ProteqFlu (--) - Powder and solvent for suspension for injection

Not authorised

- Canarypox virus, strain vCP1533, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Newmarket/2/1993), Live
- Canarypox virus, strain vCP1529, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Kentucky/94), Live

Product identification

Medicine name:
ProteqFlu (--) - Powder and solvent for suspension for injection

Active substance:
Canarypox virus, strain vCP1533, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Newmarket/2/1993), Live

Canarypox virus, strain vCP1529, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Kentucky/94), Live

Target species:
Horse

Route of administration:
Intramuscular use

Product details

Active substance and strength:

Canarypox virus, strain vCP1533, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Newmarket/2/1993), Live

Presentation_strength:6.5 log10 FAID*50 to 7.5 log10 FAID50 Reference:Hse Index:0

Canarypox virus, strain vCP1529, expressing haemagglutinin gene of Influenza A virus subtype H3N8 (A/equine/Kentucky/94), Live

Presentation_strength:6.5 log10 FAID*50 to 7.5 log10 FAID50 Reference:Hse Index:1

Pharmaceutical form:

Powder and solvent for suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

- **Horse**
  - Not applicable. 0 day 0 days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI05AD02

Legal status of supply:

Medicinal product subject to medical prescription

Authorisation status:

Surrendered

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Complete application (stand-alone) - Council Directive 81/851/EEC

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
6/03/2003

Manufacturing sites for batch release:
Boehringer Ingelheim Animal Health France

Responsible authority:
European Commission

Authorisation number:
This information is not available for this product.

Date of authorisation status change:
28/03/2007

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet